source
- AI-discovered drugs show early promise but face mixed results in clinical trialsAI is being promoted as a way to cut the cost and time of drug research and development, which can exceed $2.6 billion and take up to 15 years. Only a handful of AI‑identified compounds have enter…
- GSK drops chronic cough drug camlipixant after mixed Phase 3 resultsGSK announced it will stop investing in camlipixant for refractory chronic cough after the drug failed to meet key endpoints in a late-stage trial. The company had run two Phase 3 studies, CALM-1…